Vantis Vascular, Inc. — SEC Form D Filing

Vantis Vascular, Inc. filed an SEC Form D on July 10, 2026, reporting $18.64M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
July 10, 2026
Amount reported
$18.64M
Round stage
Seed
Industry
Medical Devices
Website
https://vantisvascular.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Vascular interventionalists face challenges in confidently, safely, and efficiently treating complex cases, particularly when navigating challenging anatomies during vascular interventions and complex PCI procedures.

Solution

Vantis Vascular develops innovative medical devices, such as the CrossFast Advanced Vascular Delivery System, to provide precise control and enhance deliverability for vascular interventionalists, allowing them to go faster and further.

Why now

There is a growing need for more advanced and precise tools in vascular interventions as procedures become more complex and challenging, particularly in areas like intravascular lithotripsy and peripheral interventions.

Verdict

Investors backed a medical device play that promised incremental efficiency gains in an established procedure. This cleared because it offered a tangible upgrade to an existing workflow, not because it introduced a novel therapeutic modality. The implicit bet was on rapid adoption by interventionalists seeking marginal improvements in complex cases. Upside was limited by the need to integrate into existing hospital procurement cycles and compete within a highly consolidated market dominated by much larger players, making an exit through acquisition of a feature set more likely than massive independent scale.

Source: SEC EDGAR Form D filing